Skip to main content
Top
Published in: Journal of Clinical Immunology 3/2022

Open Access 01-04-2022 | Vaccination | Original Article

Seasonal Betacoronavirus Antibodies’ Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization

Authors: Stefania Dispinseri, Ilaria Marzinotto, Cristina Brigatti, Maria Franca Pirillo, Monica Tolazzi, Elena Bazzigaluppi, Andrea Canitano, Martina Borghi, Alessandra Gallinaro, Roberta Caccia, Riccardo Vercesi, Paul F. McKay, Fabio Ciceri, Lorenzo Piemonti, Donatella Negri, Paola Cinque, Andrea Cara, Gabriella Scarlatti, Vito Lampasona

Published in: Journal of Clinical Immunology | Issue 3/2022

Login to get access

Abstract

SARS-CoV-2 vaccination is known to induce antibodies that recognize also variants of concerns (VoCs) of the virus. However, epidemiological and laboratory evidences indicate that these antibodies have a reduced neutralization ability against VoCs. We studied binding and neutralizing antibodies against the Spike protein domains and subunits of the Wuhan-Hu-1 virus and its alpha, beta, delta VoCs and of seasonal betacoronaviruses (HKU1 and OC43) in a cohort of 31 health care workers prospectively followed post-vaccination with BNT162b2-Comirnaty. The study of sequential samples collected up to 64 days post-vaccination showed that serological assays measuring IgG against Wuhan-Hu-1 antigens were a poor proxy for VoC neutralization. In addition, in subjects who had asymptomatic or mild COVID-19 prior to vaccination, the loss of nAbs following disease could be rapid and accompanied by post-vaccination antibody levels similar to those of naïve vaccinees. Interestingly, in health care workers naïve for SARS-CoV-2 infection, vaccination induced a rapid and transient reactivation of pre-existing seasonal coronaviruses IgG responses that was associated with a subsequent reduced ability to neutralize alpha and beta VoCs.
Appendix
Available only for authorised users
Literature
6.
7.
go back to reference Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, et al. International network for comparison of HIV neutralization assays: the NeutNet report. Unutmaz D, editor. PLoS ONE [Internet]. 2009 [cited 2021 Aug 6];4:e4505. Available from: https://dx.plos.org/https://doi.org/10.1371/journal.pone.0004505 Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, et al. International network for comparison of HIV neutralization assays: the NeutNet report. Unutmaz D, editor. PLoS ONE [Internet]. 2009 [cited 2021 Aug 6];4:e4505. Available from: https://​dx.​plos.​org/​https://​doi.​org/​10.​1371/​journal.​pone.​0004505
8.
go back to reference Burbelo PD, Goldman R, Mattson TL. A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. BMC Biotechnol. 2005;5:22.CrossRefPubMedPubMedCentral Burbelo PD, Goldman R, Mattson TL. A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. BMC Biotechnol. 2005;5:22.CrossRefPubMedPubMedCentral
9.
go back to reference Secchi M, Bazzigaluppi E, Brigatti C, Marzinotto I, Tresoldi C, Rovere-Querini P, et al. COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. Journal of Clinical Investigation [Internet]. 2020 [cited 2021 Jul 9];130:6366–78. Available from: https://www.jci.org/articles/view/142804 Secchi M, Bazzigaluppi E, Brigatti C, Marzinotto I, Tresoldi C, Rovere-Querini P, et al. COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. Journal of Clinical Investigation [Internet]. 2020 [cited 2021 Jul 9];130:6366–78. Available from: https://​www.​jci.​org/​articles/​view/​142804
12.
13.
go back to reference Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK [Internet]. Epidemiology; 2021 Aug. Available from: http://medrxiv.org/lookup/doi/https://doi.org/10.1101/2021.08.18.21262237 Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK [Internet]. Epidemiology; 2021 Aug. Available from: http://​medrxiv.​org/​lookup/​doi/​https://​doi.​org/​10.​1101/​2021.​08.​18.​21262237
16.
go back to reference Kaplonek P, Wang C, Bartsch Y, Fischinger S, Gorman MJ, Bowman K, et al. Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19 [Internet]. Immunology; 2021 May. Available from: http://biorxiv.org/lookup/doi/https://doi.org/10.1101/2021.05.11.443609 Kaplonek P, Wang C, Bartsch Y, Fischinger S, Gorman MJ, Bowman K, et al. Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19 [Internet]. Immunology; 2021 May. Available from: http://​biorxiv.​org/​lookup/​doi/​https://​doi.​org/​10.​1101/​2021.​05.​11.​443609
17.
go back to reference Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson J-P, et al. Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal betacoronaviruses. J Clin Immunol [Internet]. 2021 [cited 2021 Aug 5];41:906–13. Available from: https://link.springer.com/https://doi.org/10.1007/s10875-021-00997-6 Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson J-P, et al. Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal betacoronaviruses. J Clin Immunol [Internet]. 2021 [cited 2021 Aug 5];41:906–13. Available from: https://​link.​springer.​com/​https://​doi.​org/​10.​1007/​s10875-021-00997-6
18.
go back to reference Woldemeskel BA, Kwaa AK, Garliss CC, Laeyendecker O, Ray SC, Blankson JN. Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2. Journal of Clinical Investigation [Internet]. 2020 [cited 2021 Aug 5];130:6631–8. Available from: https://www.jci.org/articles/view/143120 Woldemeskel BA, Kwaa AK, Garliss CC, Laeyendecker O, Ray SC, Blankson JN. Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2. Journal of Clinical Investigation [Internet]. 2020 [cited 2021 Aug 5];130:6631–8. Available from: https://​www.​jci.​org/​articles/​view/​143120
22.
go back to reference Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet [Internet]. 2021 [cited 2021 May 17];397:1819–29. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673621009478 Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet [Internet]. 2021 [cited 2021 May 17];397:1819–29. Available from: https://​linkinghub.​elsevier.​com/​retrieve/​pii/​S014067362100947​8
Metadata
Title
Seasonal Betacoronavirus Antibodies’ Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization
Authors
Stefania Dispinseri
Ilaria Marzinotto
Cristina Brigatti
Maria Franca Pirillo
Monica Tolazzi
Elena Bazzigaluppi
Andrea Canitano
Martina Borghi
Alessandra Gallinaro
Roberta Caccia
Riccardo Vercesi
Paul F. McKay
Fabio Ciceri
Lorenzo Piemonti
Donatella Negri
Paola Cinque
Andrea Cara
Gabriella Scarlatti
Vito Lampasona
Publication date
01-04-2022
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 3/2022
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-021-01190-5

Other articles of this Issue 3/2022

Journal of Clinical Immunology 3/2022 Go to the issue